MPN

At the 2019 MPN Heroes® event Tammy Matuska, B.S.N., RN, known as the "lifeline to patients," was honored for her outstanding work for patients with MPN.

At the annual MPN Heroes event, Dr. David Fajgenbaum, who discovered a treatment for his own rare disorder, shared insights on turning hope into action when faced with adversity.

Here is a list of the recent trial initiations that occurred within the myeloproliferative neoplasm cancer space.

Former NHL referee Kerry Fraser opens up about living with an incurable cancer that he refuses to let sideline him.

Where does hope lie when it comes to improving the treatment landscape for rare cancers?

Collecting data about cancer through registries can help experts detect trends and patterns, leading to better care for patients.

During an interview with the “CURE Talks Cancer” podcast, retired NHL referee Kerry Fraser discussed what it is like going through treatment for essential thrombocythemia.

Retired NHL referee Kerry Fraser explained how rest and exercise both factor into his “new normal” after receiving a diagnosis of essential thrombocythemia in 2017.

Retired NHL referee Kerry Fraser shares his advice for coping with a new diagnosis after receiving his own in 2017.

A family collaborated on this essay to nominate registered oncology nurse Susan DeVictor for CURE®’s 2019 Extraordinary Healer® Award.

From today’s top entertainers to racial disparities in access to pain treatment, here’s what is making headlines in the cancer space this week.

The Food and Drug Administration granted a fast track designation to momelotinib for the treatment of patients with intermediate/high-risk myelofibrosis who have previously received a JAK inhibitor.

Only half of patients reported their blood cancer was detected while visiting a doctor after experiencing symptoms versus detection during a routine medical test or exam or while under the care of a doctor for another health condition.

A new analysis of the myMPN Patient Registry has led to some exciting new discoveries, according to researchers.

Any action, larger or small, can make a major impact in the lives of patients with a myeloproliferative neoplasm.

After her daughter was diagnosed, Celia Miltz founded the Friends of ET Research.

Angela Fleischman, M.D., Ph.D., is particularly excited for improvements in treating early-stage disease.

After realizing how little awareness there was about MPNs, one advocate looked to his TV background to help.

Jaden Persaud knows firsthand how a MPN diagnosis can affect a family's life.

The 2018 MPN Champion Awards celebrate Canadian patients, caregivers and supporters.

Understanding the disease and treatments are key aspects of being a patient advocate, explained MPN Hero Marcy Worthington.

For this MPN Hero, helping patients came naturally, she said.

To address the lack of information on this younger subset of patients, an international team of researchers analyzed a large dataset from 29 hospital centers in 12 countries.

More than 40 percent of patients with a myeloproliferative neoplasm reported that they were unsatisfied with their current pain management strategy.

In the MEASURE trial, researchers examined the affect symptom burden associated with myeloproliferative neoplasms has on patients’ lives.

At the MPN Heroes Event, Olympic skater Scott Hamilton discusses importance of advocacy and research.

While Jakafi has been providing promising outcomes so far, there are still some side effects that patients and providers should look out for.

A Danish study demonstrated smokers were 2.5 times more likely to develop a myeloproliferative neoplasm compared with their non-smoking counterparts.

Two treatments that may help patients with a potentially deadly blood cancer live longer and prevent the incidence of thrombosis (blood clots) are being underused.

After seeing encouraging phase 1 results, the phase 2 portion of a clinical trial currently evaluating the efficacy of the BET inhibitor CPI-0610 in patients with myelofibrosis has been enhanced and expanded.